Placebo + Vismodegib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Jan 23, 2014 → Jan 26, 2016
NCT ID
NCT01898598About Placebo + Vismodegib
Placebo + Vismodegib is a phase 2 stage product being developed by Roche for Basal Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01898598. Target conditions include Basal Cell Carcinoma.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02168530 | Phase 2 | Withdrawn |
| NCT01898598 | Phase 2 | Terminated |
Competing Products
20 competing products in Basal Cell Carcinoma